SCHEMBL3500213

SCHEMBL3500213

CCOC(=O)c1cc2cc(-c3ccc(Cl)cc3)ccc2n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 0.49
NOD1 Q9Y239 1/20 0.49
MAPT P10636 3/20 0.48
GABRA2 P47869 4/20 0.48
GABRB2 P47870 4/20 0.48
NPSR1 Q6W5P4 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
IDO1 P14902 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 1/20 0.45
MAOA P21397 1/20 0.45
ALPL P05186 1/20 0.44
TARBP2 Q15633 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
UTS2R Q9UKP6 1/20 0.43
LGALS8 O00214 1/20 0.43
LGALS3 P17931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498975 0.90 NOD2 (0.52) NOD2NOD1MAPTGABRA2GABRB2
SCHEMBL1253237 0.89 RXFP1 (0.56) NOD2NOD1MAPTNPSR1KDM4E
SCHEMBL7626390 0.81 NOD2 (0.53) NOD2NOD1MAPTGABRA2GABRB2
SCHEMBL31264263 0.81 NOD2 (0.53) NOD2NOD1MAPTGABRA2GABRB2
SCHEMBL11529770 0.81 MAPT (0.67) NOD2NOD1MAPTRXFP1L3MBTL1
SCHEMBL3500225 0.81 KDM4E (0.59) KDM4ERXFP1HPGDSMN1; SMN2HSD17B10
SCHEMBL5889514 0.80 MAPT (0.62) NOD2NOD1MAPTKDM4EL3MBTL1
SCHEMBL9144581 0.80 CLK1 (0.55) MAPTKDM4EL3MBTL1LMNAMAOA
SCHEMBL7218114 0.79 NOD2 (0.52) NOD2NOD1MAPTGABRA2GABRB2
SCHEMBL1173839 0.79 MAPT (0.52) NOD2NOD1MAPTKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 NOD2 1176/4885NOD1 2074/4885MAPT 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.